Arguments have been made that private insurance agencies would be invested in providing such care for donors, as the procedure would become relatively standard given the long waitlist for organs.
This designation requires multiple observational studies, clinical studies, waitlist-controlled studies, and within subject and intrasubject replication studies that demonstrate efficacy.